Clinical safety and efficacy of a hydrophilic acrylic intraocular lens in a real-world population: a 1-year follow-up retrospective study

Björn Johansson 1, Ana C. S. Daniel 2, Claudia Herbers 2, Matthias Gerl 3 and Florian T. A. Kretz 2*

Abstract

Background: This multicentre, retro-prospective real-world study evaluated the visual, refractive and safety outcomes of a monofocal lens 1 year after implantation in cataract patients with or without pre-existing ocular pathologies.

Methods: Records from 4 centres in Germany and Sweden were reviewed to select eyes with aged-related cataracts, having undergone crystalline lens extraction by phacoemulsification and implantation of a CT ASPHINA 409 IOL. Preoperative, 1-month and 3-month postoperative data was collected retrospectively. In addition, included patients attended a prospective visit 12 months or later after surgery. The examination included: monocular uncorrected (UDVA) and corrected distance visual acuity (CDVA), subjective refraction, slit-lamp examination, optical biometry, intraocular pressure (IOP), endothelial cell count and postoperative complications.

Results: 282 eyes, including 94 with pre-existing ocular pathologies, were analysed. Twelve months after the surgery, 95% of eyes achieved monocular CDVA equal or better than 0.3 logMAR, mean postoperative CDVA was 0.06 ± 0.17 logMAR, and mean UDVA 0.31 ± 0.29 logMAR. Visual acuity outcomes were better in eyes with no pre-existing ocular pathologies, but both groups showed a statistically significant improvement after surgery compared with preoperative values (p ≤ 0.002). The mean sphere and spherical equivalent values also improved significantly postoperatively (p = 0.003). Overall, 62.1% of eyes had spherical equivalent within ±0.5 D and 80.9% within ±1.0 D. The IOL was stable in the capsular bag as demonstrated by tilt and decentration measurements. IOP, corneal status, and endothelial cell count values were in the normal range. Nd:YAG treatment was performed on 9.9% of the eyes.

Conclusion: The implantation of the monofocal CT ASPHINA 409 IOL was beneficial to restore vision in eyes with or without concomitant ocular pathology such as macular degeneration, glaucoma, Sicca syndrome, epiretinal membrane, cornea guttata, or amblyopia. Good to excellent long-term visual and refractive outcomes, and a low rate of complications in both healthy and pathological eyes were found 12 months after the surgery.

Trial registration: Trial registered on under the identification NCT03145103 (date of registration 9 May 2017).

Keywords: Monofocal, Intraocular lens, IOL, Real-world, Visual outcome, Ocular pathology, Human

© The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Cataract afflicts millions of people worldwide and is still today the major cause of blindness. It is estimated that roughly 20 million people are blind because of bilateral cataract worldwide [1]. In addition to the reduction in visual acuity, cataract has been correlated with depression, decreased quality of life for the patients and their caretakers and increased mortality rates in the elderly [1].

Many models of intraocular lenses (IOLs) are currently available on the market to adapt to the widest possible population and fulfil, when possible, the exact postoperative desires of the patients. Premium IOLs, including toric, multifocal and more recently extended depth of focus lenses and accommodative IOLs [2] restore distance visual function, and can also mimic more closely the optimal performance of the eye.

Despite this technological progress, monofocal IOLs are still the most widely implanted lenses worldwide. Reasons for their popularity include lower price, patient preference [3], patient natural sensitivity to glare and halos [3], or the presence of coexisting ocular conditions [4].

The CT ASPHINA 409 IOL is an aspheric, aberration neutral, monofocal lens designed for implantation through an incision of 1.8 mm or more. The design of the lens features four-point plate haptics and one-piece construction from a hydrophilic acrylic material with hydrophobic surface properties. This lens is commercialised in Europe since 2006. This retro-prospective study was designed to evaluate the visual and refractive outcomes as well as the safety of the CT ASPHINA 409, 1 year after implantation in real-world cataract patients.

Methods
Patient population
This multicentre, retro-prospective, clinical study was conducted at 4 sites in Germany and Sweden between August 2017 and June 2018. The protocol was reviewed and approved by the Ethics Committee of each site, followed the tenets of the Declaration of Helsinki and fully complied with the International Conference on Harmonization and Good Clinical Practice guidelines. All patients provided a written informed consent prior to enrolment. This trial was registered before the study began with ClinicalTrials.gov, number NCT03145103.

The study included patients who had previously undergone uncomplicated age-related cataract extraction and in-the-bag implantation of a CT ASPHINA 409 IOL in one eye (retrospective patient selection). Inclusion and exclusion criteria were strictly defined to only take into consideration preoperative aspects. Patients for whom CDVA was not available preoperatively or patients with preoperative CDVA better than 0.3 logMAR were excluded from the study. All the remaining patients were invited to attend a postoperative visit at least 12 months after the implantation (prospective data collection).

The primary objective of the trial was to compare the postoperative rate of eyes with CDVA 0.3 logMAR or better to the threshold value given in ISO 11979-7:2014 (92.5%). The minimal recommended number of subjects to achieve this objective was 282.

Surgery
Surgeries were performed by experienced surgeons with at least 3 years of practice according to their normal protocol. Standard single plane, self-sealing clear corneal incision, capsulorhexis and conventional phacoemulsification was used in all cases. Phacoemulsification was performed through a 1.8 mm incision in 3.9% of cases, a 2.0 mm incision in 48.9% of cases, a 2.2 mm in 2.5% of cases or a 2.7 mm in 44.7% of cases. After a continuous circular capsulorhexis of about 5.5 mm and hydrodissection, the cataract was removed by phacoemulsification with stop-and-chop technique. The CT ASPHINA 409 IOL was subsequently implanted in the capsular bag using a qualified injector in combination with a viscoelastic device. At the end of the surgery, any residual ophthalmic viscoelastic device was thoroughly removed by irrigation, and side ports and main incision were sealed by hydration. Postoperative treatment and medication were given according to the routine procedure in each centre.

The IOL specifications are summarized in Table 1.

Retrospective data collection
Preoperative, surgery-related, 1- and 3-month postoperative data was collected retrospectively when available. Preoperative data collection included medical history, relevant concomitant pathologies and treatments, monocular uncorrected and corrected distance visual acuities (UDVA and CDVA), subjective refraction, biometry, intraocular pressure, endothelial cell count and slit-lamp examination results. Surgery-related data included intraoperative complications, IOL power and expected postoperative refraction. Finally, postoperative monocular visual acuity, and refraction outcomes were collected 1 and 3 months after the surgery when available along with any complications.

Prospective, postoperative examinations
During the postoperative visit planned at 12 months or more, the patients received a detailed ophthalmologic examination including UDVA and CDVA, subjective refraction, biometry, intraocular pressure, endothelial cell count and slit-lamp examination results. Surgery-related data included intraoperative complications, IOL power and expected postoperative refraction. Finally, postoperative monocular visual acuity, and refraction outcomes were collected 1 and 3 months after the surgery when available along with any complications.
Jena, Germany), intraocular pressure and endothelial cell count. Adverse events, including posterior capsule opacification (PCO) and neodymium-doped yttrium aluminium garnet (Nd:YAG) rates, were recorded during the follow-up period.

Statistical analysis
Statistical analysis was performed using SAS Version 9.4 (SAS Institute Inc., Cary, USA). Quantitative endpoints are presented as the mean ± standard deviation and range (minimum; maximum). Qualitative endpoints are presented in terms of number and percentage of each modality and number of patients. In all cases, a \( p \)-value less than 0.05 was considered as statistically significant. For quantitative endpoints, Student’s \( t \)-test for parametric test or Wilcoxon test for non-parametric tests were used. For qualitative endpoints, standard Chi-square test for parametric tests or Fisher exact test or Cochran-Mantel-Haenszel test for non-parametric tests were used.

Results
Patient characteristics
A total of 282 patients (safety population) were included into the study after signing the informed consent; they attended the postoperative visit after a mean follow-up of 510 ± 114 days. Incision size ranged from 1.8 mm to 2.7 mm (mean 2.31 ± 0.35 mm). The preoperative characteristics are given in Table 2.

Amongst the selected eyes, 2 subpopulations were defined. The “healthy eye” group that included 188 eyes (66.66% of overall population) with cataract but without any ocular pathology that could potentially affect visual acuity. And the “pathological eye” group that included 94 eyes (33.3% of overall population) with at least one concomitant pathology potentially affecting visual acuity. The main pathologies reported were: macular degeneration (42.6%), glaucoma (22.3%), Sicca syndrome (11.7%), epiretinal membrane (9.6%), cornea guttata (9.6%), hypertony (9.6%) and amblyopia (4.3%). In addition, 10.6% of the eyes had other retinal pathologies (e.g. diabetic retinopathy, retinal scar), 8.5% had other various macular abnormalities (e.g. atrophy or oedema), 7.5% had corneal abnormalities (e.g. scar, verticillata, vacuoles) and 5.1% had other various eye abnormalities (e.g. shallow anterior chamber or excavated papilla).

Details of the analysed data sets are given in Fig. 1.

Visual acuity
Monocular CDVA and monocular UDVA per visual acuity class are shown in Fig. 2 and Fig. 3 for the three populations (safety population, “healthy eye” population and “pathological eye” population).
At 12 months, 95% (CI 92.5%; 97.5%) of the eyes in the safety population had monocular CDVA equal or better than 0.3 logMAR. The 14 eyes that did not reach this visual acuity level were very often multi-pathological eyes. An exhaustive list of the eye-related pathologies likely to have contributed to the reduced visual acuity outcome is presented in Table 3. Amongst these eyes, 5 had a postoperative gain in visual acuity including 4 who gained 1 line or more. Four eyes experienced no change in visual acuity and 5 experienced a loss in visual acuity. Mean postoperative CDVA in the safety population was 0.06 ± 0.17 logMAR (p < 0.001 versus preoperative value). There was no statistically significant change in CDVA during the follow-up (p = 0.759).

In the “healthy eye” group, 98.9% (CI 100%; 94.7%) of the eyes reached monocular CDVA equal or better than 0.3 logMAR and the mean CDVA at 12 months was 0.02 ± 0.11 logMAR. In the “pathological eye” group, 87.2% (CI 93.9%; 80.4%) of eyes reached monocular CDVA equal or better than 0.3 logMAR and the mean CDVA at 12 months was 0.15 ± 0.24 logMAR. In these 2 subpopulations, CDVA improved significantly postoperatively compared with baseline values (p < 0.001).

Mean UDVA values at 12 months were the following: 0.31 ± 0.29 logMAR in the safety population, 0.29 ± 0.30 logMAR in the “healthy eye” group, and 0.36 ± 0.27 logMAR in the “pathological eye” group. The improvement was statistically significant in the three groups compared with preoperative values (p ≤ 0.002).

Table 2 Preoperative patient characteristics

| Patient characteristics | n* | Mean ± SD | Range |
|-------------------------|----|-----------|-------|
| Age (years)             | 282| 73 ± 7.7  | 49; 91 |
| Gender (% men/women)    | 282| 46.5 / 53.5|       |
| Axial length (mm)       | 280| 23.82 ± 1.43| 21.47; 33.83 |
| Anterior chamber depth (mm) | 277| 3.16 ± 0.42 | 1.91; 4.82 |
| IOL power (D)           | 282| 19.89 ± 3.24| 1.0; 27.5 |
| Formula                 | 279|            |       |
|                         |    | Haigis: 52.7% | SRK/T: 47.0% | Holladay: 0.4% |
| Expected postoperative spherical equivalent (D) | 278| -0.43 ± 0.97 | -6.27; 2.84 |

| Refraction              |     |           |
|-------------------------|-----|-----------|
| Sphere (D)              | 149| -0.65 ± 3.14| -16.0; 6.5 |
| Cylinder (D)            | 148| -0.87 ± 0.72| -3.5; 0   |
| Spherical equivalent (D)| 148| -1.07 ± 3.15| -16.0; 6.0|

| Visual acuity           |     |           |
|-------------------------|-----|-----------|
| UDVA                    | 53  | 0.84 ± 0.45| 0.2; 2.3  |
| CDVA                    | 280 | 0.48 ± 0.28| 0.1; 2.3  |

* Due to the retrospective nature of the trial, not all individual preoperative values were available. In particular, subjective refraction and UDVA were not routinely measured preoperatively in all sites.

Refration

In the overall population the mean sphere and spherical equivalent values improved significantly: from −0.65 ± 3.14 D at the baseline visit to 0.11 ± 1.10 D at the end of the follow-up (p = 0.003) for the sphere and from −1.07 ± 3.15 D to −0.29 ± 1.09 D, p = 0.003 for the spherical equivalent. Over the same period, there was a slight but non-significant improvement of the cylinder (from −0.87 ± 0.72 D to −0.81 ± 0.63 D, p = 0.068).

Between the 1-month follow-up and the end of the study, there was no detectable refractive shift (p ≥ 0.470 for sphere, cylinder and spherical equivalent).

Twelve months postoperatively, 62.1% of eyes had spherical equivalent within ±0.5 D and 80.9% within ±1.0 D. In terms of predictability, the mean difference between expected refraction and the postoperative spherical equivalent at 12 months was −0.15 ± 0.51 D (p < 0.001). There was no difference in predictability between the 2 most used formulas (Haigis; SRK/T). At the 12-month follow-up, 67.0 and 93.0% of patients achieved a final spherical equivalent within ±0.5 D and ±1 D respectively of the predicted figure.

Safety

In the overall population, 277 (98.2%) of the IOLs were centred. The maximum horizontal or vertical decentration in the 5 (1.8%) remaining eyes was ≤1 mm. Tilt was noticed in 1 eye only and was also minimal (1 degree).
Overall, intraocular pressure, corneal status, inflammatory reaction and endothelial cell count were all normal at the 12-month follow-up. More specifically, intraocular pressure decreased from 16.16 ± 3.40 mmHg to 13.52 ± 3.31 mmHg between the preoperative and the 12-month visits ($p < .001$). Corneal opacification was observed in only 1 eye (0.4%) in a patient who was also diagnosed with band keratopathy and cornea guttata. No signs of inflammatory cells, fibrin or flare were observed at 12 months. And the endothelial cell count was 2096 ± 483 cells/mm² at the end of the follow-up.

The main postoperative ocular events observed at the 12-month follow-up were the following: 13 (4.6%) patients reported dry eye sensation, 6 (2.1%) patients developed dry age-related macular degeneration, 6 (2.1%) had vitreous detachment, 5 (1.8%) had cystoid macular oedema, 2 (0.7%) had iritis and 1 (0.4%) had corneal oedema. Amongst these events, only 3 cases of cystoid macular oedema were described as 'likely' or 'certainly' related to the surgery and no event was described as related to the IOL. No IOL dislocation or explantation occurred during the study. Finally, 27 (9.9%) patients received a Nd:YAG treatment during the follow-up.

**Discussion**

This study evaluated the real-world performance and safety of the monofocal, aspheric CT ASPHINA 409 IOL 1 year after implantation in eyes with age-related cataract.

In terms of performance, the CT ASPHINA 409 IOL fulfilled ISO 11979-7:2014 criteria, with 95% of the eyes reaching a monocular CDVA equal or better than 0.3
logMAR. This percentage even increased to 98.9% when considering the “healthy eye” group. This outcome is comparable to the data communicated by Alcon with a similar lens, the monofocal, aspheric SA60WF IOL: 96.9% in a population of 129 eyes [5]. The primary outcomes of this trial also compare favourably with the real-world data published from the EUREQUO database [6]. Data on more than 368,000 cataract extractions were analysed, including 25.6% eyes with an ocular comorbidity, and 90% of cases achieved CDVA of 0.3 logMAR. Logistic regression analysis demonstrated that ocular comorbidity and postoperative complications were the two most decisive variables for good clinical outcomes [6]. Mean CDVA (0.06 ± 0.17 logMAR) and UDVA (0.31 ± 0.29 logMAR) at 12 months were slightly higher than values previously reported in prospective clinical trials with similar IOLs, presumably on healthy eyes [7, 8]. However, the outcomes of this study are similar to real-world CDVA values reported by EUREQUO (0.057 ± 0.26 logMAR) [9], and the Royal College of Ophthalmologists (0.16 ± 0.30 logMAR) [10]. These two studies also included eyes with concomitant

![Fig. 2 Distribution of monocular corrected distance visual acuity (CDVA) at 12 months](image)

![Fig. 3 Distribution of monocular uncorrected distance visual acuity (UDVA) at 12 months](image)
ocular pathologies (respectively 27.3 and 36.9% of the studied population).

In this study, good refractive predictability was achieved with 67 and 93.0% of eyes respectively within ±0.5 D and ±1 D of the predicted value. These values were consistent with benchmark values previously reported [11, 12] and slightly lower than the figures reported in the EUREQUO study (93.8% of eyes within ±1 D and 73.7% within ±0.5 D) [9]. The mean difference between the expected refraction and the postoperative spherical equivalent was very moderate (−0.15 ± 0.51 D) indicative of a high accuracy of the predicted refraction. The targeted spherical equivalent was −0.43 ± 0.97 D and the achieved value at 12 months −0.29 ± 1.09 D. Although this difference was statistically significant (p < 0.01), its clinical significance was questionable as the value was very close to zero and well below a quarter of a dioptre.

With regards to safety aspects, the overall number of postoperative ocular events was low. Furthermore, they appear to be related to the surgical procedure in general rather than to the IOL itself and do not outweigh the benefits of the procedure in the studied eye.

Table 3

| Case number | CDVA (logMAR) Preop. | CDVA (logMAR) 12 months | Factors contributing to CDVA > 0.3 logMAR |
|-------------|----------------------|-------------------------|------------------------------------------|
| 1           | 0.4                  | 0.6                     | Diabetic macular oedema; diabetic proliferative retinopathy; clinically significant PCO requiring Nd:YAG |
| 2           | 1.0                  | 0.92                    | Amblyopia                                 |
| 3           | 0.4                  | 0.4                     | No distinct ocular disorders despite diabetes; clinically significant PCO requiring Nd:YAG |
| 4           | 2.3                  | 0.7                     | Cornea guttata; macular atrophy; early stage band keratopathy |
| 5           | 1.3                  | 1.3                     | Retinal scar (geographic atrophy); amblyopia |
| 6           | 0.4                  | 0.5                     | Dry macular degeneration; geographic atrophy |
| 7           | 0.6                  | 0.6                     | Amblyopia; macular traction; retinoschisis |
| 8           | 0.4                  | 0.5                     | Dry macular degeneration; adult vitelliform maculopathy |
| 9           | 0.4                  | 1.0                     | Cornea guttata; ocular hypertension requesting surgical intervention (trabeculectomy) and leading to hyperaemia and hyphema |
| 10          | 0.4                  | 0.4                     | Glaucoma; dry macular degeneration; drusen macula; glaucomatous papilla; amblyopia |
| 11          | 0.52                 | 0.34                    | Epiretinal membrane                       |
| 12          | 0.3                  | 0.4                     | No distinct ocular disorders despite diabetes mellitus; clinically significant PCO requiring Nd:YAG |
| 13          | 0.6                  | 0.32                    | Age-related macular degeneration; transition from drusen age-related macular degeneration to neovascular wet age-related macular degeneration; corneal erosion; clinically significant PCO |
| 14          | 0.7                  | 0.38                    | Slight age-related macular degeneration with drusen; vitreous detachment; clinically significant PCO requiring Nd:YAG |

Table 3 List of the eye-related pathologies experienced by the 14 patients from the safety population not reaching monocular CDVA equal or better than 0.3 logMAR

Ocular co-pathology was found in 33.3% of the patients, which is consistent with rates previously reported in real-world analyses [9, 10]. The nature of the co-pathologies was also consistent with these previous reports, with age-related macular degeneration, glaucoma, diabetic retinopathy and amblyopia being the most frequently recorded.

Postoperative corrected and uncorrected visual outcomes were slightly inferior in the group of eyes with concomitant pathology compared with the population of healthy eyes. However, the benefit/risk ratio for both populations was still favourable. Deciding to implant an IOL in an eye with concomitant pathology is often
challenging: the stability of the disease, its expected progression over time, and the anticipated usefulness of the treatment are aspects that should be taken into consideration. The results of this study are consistent with previous publications that showed that phacoemulsification combined with posterior chamber IOL implantation in pathological eyes can result in favourable anatomic and visual outcomes in patients with macular degeneration [16, 17] glaucoma, [18–20] proliferative diabetic retinopathy [21, 22] and amblyopia [8, 23]. Additional studies would be required to further evaluate long-term complications and visual performance.

Conclusion
As globally the population over 60 years of age continues to increase, it is estimated that the number of patients undergoing cataract surgery will keep on rising. The number of procedures performed on multi-pathological eyes will follow the same trend and it is important to provide these eyes with safe and performant solutions. Overall, findings from this study indicate good to excellent visual and refractive outcomes, with a low rate of complications up to 1 year following implantation of the CT ASPHINA 409 in healthy eyes and in eyes with concomitant pathology.

Abbreviations
CDVA: Corrected distance visual acuity; CI: Confidence interval; D: Dioptre; EUREQUO: European registry of quality outcomes for cataract and refractive surgery; IOL: Intraocular lens; IOP: Intraocular pressure; ISO: International organization for standardization; LogMAR: Logarithm of minimum angle of resolution; Nd:YAG: Neodymium-doped yttrium aluminium garnet; PCO: Posterior capsule opacification; SD: Standard deviation; UDVA: Uncorrected distance visual acuity

Acknowledgments
To Marie Berry (Medical Writer at Carl Zeiss Meditec) for assistance with writing and editing the manuscript.

Authors’ contributions
BJ, AD, CH, MG, and FK actively contributed to the acquisition of data at their respective investigational site. The manuscript was drafted by BJ and FK with active participation of a medical writer (see acknowledgements section). BJ, AD, CH, MG, and FK substantially revised the manuscript and approved its final version.

Funding
This study was funded by Carl Zeiss Meditec AG, Jena, Germany. The sponsor was responsible for preparing the protocol and funded a contract research organization to conduct the study, to manage and monitor the data, and to perform the statistical analysis.

Availability of data and materials
The data that support the findings of this study are available from Carl Zeiss Meditec AG but restrictions apply to their availability. The data are available from Carl Zeiss Meditec AG upon reasonable request.

Ethics approval and consent to participate
This study was approved by the following Ethical Committees: Medical Association Westfalen-Lippe and Westphalan Wilhelms University, Münster, Germany; Linköpings University, Linköping, Sweden; Bavarian State Medical Association, München, Germany. Written informed consent was obtained from all participants before inclusion. The study was performed in accordance with the tenets of the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
Dr. med. Florian Kretz (EBO) is a consultant for Carl Zeiss Meditec, Oculentis, Mynosys, Rayner, Biotech, Glaukos LensAR and Teleon Surgical. His research is partially financed by Carl Zeiss Meditec, PhysIOL, Santen, AVS, Oculentis, Acufocus, Hoya, Johnson & Johnson, iSTAR Medical, Mynosys, Biotech, Infinite Vision and Glaukos. He receives travel reimbursement and honoraria from Carl Zeiss Meditec, PhysIOL, Santen, AVS, Oculentis, Acufocus, Hoya, Nidek, Mynosys, Biotech, Infinite Vision and Glaukos. VSY, MST and LensAR. MD PhD Björn Johansson (FBO) is a consultant for Alcon, Bausch & Lomb, Carl Zeiss Meditec, Johnson & Johnson and Théa Laboratoires. The other authors have no competing interests to declare.

Author details
1Division of Sensory Organs and Communication, Department of Biomedical and Clinical Sciences, Linköping University, SE58183, Linköping, Sweden. 2Augentagesklinik Rheine, Osnabrücker Straße 233-235, 48429 Rheine, Germany. 3Augenklinik Ahaus, Am Schlossgraben 13, 48683 Ahaus, Germany.

Received: 6 January 2020 Accepted: 1 June 2020
Published online: 11 June 2020

References
1. Lee CM, Afshari NA. The global state of cataract blindness. Curr Opin Ophthalmol. 2017;28:98–103.
2. Zhou H, Zhu C, Xu W, Zhou F. The efficacy of accommodative versus monofocal intraocular lenses for cataract patients: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(40):e12693.
3. de Silva SR, Evans JR, Samantha R, Evans JR, Kirithi V, Zaei M, Leyland M. Multifocal versus monofocal intraocular lenses after cataract extraction. Cochrane Database Syst Rev. 2016;12:CD003169.
4. Zvončanin J, Zvončanin E. Premium intraocular lenses: the past, present and future. J Curr Ophthalmol. 2018;30:287–96.
5. Alcon Laboratories Inc. Product Information: AcrySof Aspheric UV Absorbing IOL 40–500-214-NEW. https://p.widencdn.net/to32k/40-500-214_us_en. Accessed 16 Dec 2019.
6. Lundström M, Barry P, Henry Y, Rosen P, Stenevi U. Visual outcome of cataract surgery: study from the European registry of quality outcomes for cataract and refractive surgery. J Cataract Refract Surg. 2013;39:673–9.
7. Lee K-M, Park S-H, Joo C-K. Comparison of clinical outcomes with three different aspheric intraocular lenses. Acta Ophthalmol. 2011;89:40–6.
8. Cadarso L, Iglesias A, Ollero A, Pita B, Montés-Micó R. Postoperative optical aberrations in eyes implanted with AcrySof spherical and aspheric intraocular lenses. J Refract Surg. 2008;24:811–6.
9. Lundström M, Brocato L, Dickman M, Henry Y, Manning S, Rosen P, Stenevi U, Tassignon MJ. EUREQUO annual report 2017 based on data from the European registry of quality outcomes for cataract and refractive surgery. 2017. http://www.eurequo.org/wp-content/uploads/2018/11/EUREQUO_Annual_Report2017.pdf. Accessed 16 Dec 2019.
10. Day AC, Donachie, P H J, Sparrow JM, Johnston RL. The Royal College of Ophthalmologists’ National Ophthalmology Database study of cataract surgery: report 1, visual outcomes and complications. Eye (Lond). 2015;29:552–60.
11. Hahn U, Krümmenauer F, Kölbl B, Neuhann T, Shayan-Arayi K, Schmickler S, et al. Determination of valid benchmarks for outcome indicators in cataract surgery: a multicenter, prospective cohort trial. Ophthalmology. 2011;118:2105–012.
12. Gale RP, Saldana M, Johnston RL, Zuberbuhler B, McKibbin M. Benchmark standards for refractive outcomes after NHS cataract surgery. Eye (Lond). 2009;23:149–52.
13. Mencacci R, Cennamo M, Venturi D, Vignapiano R, Favuzza E. Visual outcome, optical quality, and patient satisfaction with a new monofocal IOL enhanced for intermediate vision: preliminary results. J Cataract Refrat Surg. 2020;46:378–87.
14. Scordia V, Sosa M, Lucisano A, Lanza M, Giannaccare G. A preliminary comparative study of visual performance between two newly commercially

Page 8 of 9 Johansson et al. BMC Ophthalmology (2020) 20:224
available monofocal intraocular lenses implanted during cataract surgery. Clin Ophthalmol. 2020;14:831–5.
15. Pedrotti E, Carones F, Aiello F, Mastropasqua R, Bruni E, Bonacci E, Talli P, Nucci C, Mariotti C, Marchini G. Comparative analysis of visual outcomes with 4 intraocular lenses: Monofocal, multifocal, and extended range of vision. J Cataract Refract Surg. 2018;44(2):156–67.
16. Gayton JL, MacKool RJ, Ernest PH, Seabolt RA, Dumont S. Implantation of multifocal intraocular lenses using a magnification strategy in cataractous eyes with age-related macular degeneration. J Cataract Refract Surg. 2012; 38:415–8.
17. Furino C, Ferrara A, Cardascia N, Besozzi G, Alessio G, Sborgia L, Boscia F. Combined cataract extraction and intravitreal bevacizumab in eyes with choroidal neovascularization resulting from age-related macular degeneration. J Cataract Refract Surg. 2009;35:1518–22.
18. Kubota T, Toguri I, Onizuka N, Matsuura T, Phacoemulsification and intraocular lens implantation for angle closure glaucoma after the relief of pupillary block. Ophthalmologica. 2003;217:325–8.
19. Jacobi PC, Dietlein TS, Kriegstein GK. The risk profile of trabecular aspiration versus trabeculectomy in glaucoma triple procedure. Graefes Arch Clin Exp Ophthalmol. 2000;238:545–51.
20. Inatani M, Tanihara H, Muto T, Honjo M, Okazaki K, Kido N, Honda Y. Transient intracocular pressure elevation after trabeculectomy and its occurrence with phacoemulsification and intraocular lens implantation. Jpn J Ophthalmol. 2001;45:288–92.
21. Kim DH, Chung JW, Chung H, Yu HG. Phacoemulsification and foldable intraocular lens implantation combined with vitrectomy and silicone oil tamponade for severe proliferative diabetic retinopathy. J Cataract Refract Surg. 2004;30:1721–6.
22. Ohara K, Kato S, Hori S, Kitano S. Tilt and decentration of the intraocular lens following combined vitrectomy and pars plana lensectomy. Acta Ophthalmol Scand. 2006;84:388–9.
23. de Wit DW, Diaz JM, Moore TCB, Moore JE. Refractive lens exchange for a multifocal intraocular lens with a surface-embedded near section in mild to moderate anisometropic amblyopic patients. J Cataract Refract Surg. 2012; 38:1796–801.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.